Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

VGHCX vs IDNA overlap: 17% of top holdings shared

Bottom line

How much do VGHCX and IDNA overlap?

17% of their top holdings overlap by weight. 5 securities appear in both funds' top 25, making up 14.1% of VGHCX's assets and 19.6% of IDNA's. They are substantially different portfolios, so owning both adds real diversification.

Updated Nov 22, 2026

Overlap at a glance

VGHCXIDNA
Weight overlap (top 25)17%
Shared holdings5
Weight in shared holdings14.1%19.6%
Total positions9761
Expense ratio0.33%0.47%
Holdings as ofJul 31, 2026Jul 31, 2026

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)

Holdings VGHCX and IDNA have in common

Holding% of VGHCX% of IDNAOverlap
Merck & Co Inc5.44%3.91%3.91%
Gsk Plc3.00%3.63%3.00%
Vertex Pharmaceuticals Inc2.36%3.87%2.36%
Regeneron Pharmaceuticals Inc2.14%4.35%2.14%
Roche Holding AG1.18%3.85%1.18%

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in VGHCX

  1. Eli Lilly & Co — 8.61%
  2. Johnson & Johnson — 4.83%
  3. AstraZeneca PLC — 4.59%
  4. UnitedHealth Group Inc — 4.05%
  5. Edwards Lifesciences Corp — 2.56%
  6. Intuitive Surgical Inc — 2.52%
  7. CVS Health Corp — 2.52%
  8. Cencora Inc — 2.47%
  9. AbbVie Inc — 2.30%
  10. Danaher Corp — 2.18%
  11. Novartis AG — 1.91%
  12. Elevance Health Inc — 1.83%
  13. Argenx SE — 1.68%
  14. HCA Healthcare Inc — 1.68%
  15. Ucb Sa — 1.67%

Only in IDNA

  1. BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 10.39%
  2. Bayer Aktiengesellschaft — 4.81%
  3. Twist Bioscience Corp — 4.79%
  4. Revolution Medicines, Inc. — 4.55%
  5. Genmab A/s — 4.23%
  6. Incyte Corporation — 4.23%
  7. Moderna, Inc. — 4.19%
  8. Takeda Pharmaceutical Company Limited — 4.05%
  9. Ipsen Sa — 3.84%
  10. BioNTech SE — 3.73%
  11. Exelixis, Inc. — 3.65%
  12. Sanofi Sa — 3.46%
  13. IDEAYA Biosciences Inc — 3.36%
  14. Immunitybio Inc — 3.07%
  15. Arcus Biosciences, Inc. — 2.68%

Asset mix

Asset typeVGHCXIDNA
Stocks97.6%96.0%
Cash & short-term funds0.1%10.5%
Other—3.8%
Repurchase agreements2.2%—

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)

Country mix

CountryVGHCXIDNA
US77.6%70.2%
DE—8.5%
FR—7.8%
GB7.6%3.7%
JP4.8%6.0%
CH4.5%5.4%
DK1.4%4.2%
BE3.4%—

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)

Check another pair

FAQ

How much do VGHCX and IDNA overlap?
About 17% by weight. 5 securities appear in both funds' top 25 holdings; they make up 14.1% of VGHCX's assets and 19.6% of IDNA's. They are substantially different portfolios, so owning both adds real diversification.
What stocks do VGHCX and IDNA have in common?
The largest shared holdings are Merck & Co Inc, Gsk Plc, Vertex Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Roche Holding AG.
Should I own both VGHCX and IDNA?
Their portfolios are mostly different, so owning both can add diversification. Check how each fits your overall allocation.
Which holds more stocks, VGHCX or IDNA?
VGHCX is broader, with 97 positions versus 61 for IDNA. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.